Related Experiment Video
Updated: May 18, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Functional p53 determines docetaxel sensitivity in prostate cancer cells
Chengfei Liu1, Yezi Zhu, Wei Lou
1Department of Urology, University of California at Davis, Sacramento, California 95817, USA.
Docetaxel resistance in prostate cancer is linked to p53 status. Functional p53 enhances docetaxel sensitivity and apoptosis, while its absence reduces sensitivity in castration-resistant prostate cancer (CRPC) models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Docetaxel is a primary treatment for castration-resistant prostate cancer (CRPC).
- Acquired docetaxel resistance presents a significant challenge in advanced prostate cancer treatment.
- Understanding resistance mechanisms is critical for improving patient outcomes.
Purpose of the Study:
- To investigate the role of p53 in mediating docetaxel sensitivity in prostate cancer cells.
- To determine if p53 status influences apoptosis induction by docetaxel.
- To explore therapeutic strategies targeting p53 for overcoming docetaxel resistance.
Main Methods:
- Examined docetaxel effects on human prostate cancer cell lines (DU145, PC3, LNCaP, C4-2) in vitro.
- Analyzed p53 expression and phosphorylation using Western blot.
- Manipulated p53 levels via shRNA-mediated silencing and wild-type p53 overexpression.
Main Results:
- Prostate cancer cells with functional p53 (LNCaP, C4-2) showed higher sensitivity to docetaxel than those with mutant or null p53 (DU145, PC3).
- Docetaxel treatment dose-dependently increased apoptosis in p53-expressing cells and induced p53 phosphorylation at Ser15.
- p53 knockdown abrogated docetaxel-induced apoptosis, while p53 overexpression in resistant cells enhanced sensitivity.
Conclusions:
- Docetaxel treatment induces p53 phosphorylation.
- p53 status is a critical determinant of docetaxel sensitivity in prostate cancer.
- Targeting p53 may represent a viable strategy to overcome docetaxel resistance in CRPC.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase